CorMedix (CRMD) Research & Development (2010 - 2026)
CorMedix (CRMD) posted Research & Development of -$2.7 million for Q4 2025, down 124.24% sequentially from $11.2 million in Q3 2025, and down 110.22% YoY from $26.5 million in Q4 2024.
CorMedix (CRMD) Research & Development (2010 - 2026) Analysis & Trends
CorMedix has reported Research & Development for 15 years, with the latest figure at -$2.7 million in Q4 2025.
- Quarterly Research & Development fell 110.22% year-over-year to -$2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.1 million (down 60.22% YoY) and the FY2025 annual result came in at $19.3 million, down 32.72% from the prior year.
- Research & Development declined to -$2.7 million in Q4 2025 per CRMD's latest filing, from $11.2 million in the prior quarter.
- Over five years, Research & Development peaked at $26.5 million in Q4 2024 and troughed at -$2.7 million in Q4 2025.
- A 5-year average of $4.4 million and a median of $3.2 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 1438.41% in 2025, down 110.22% in 2025.
- Over 5 years, Research & Development stood at $3.2 million in 2021, then dropped by 12.12% to $2.8 million in 2022, then advanced by 12.53% to $3.2 million in 2023, then surged by 728.93% to $26.5 million in 2024, then sank by 110.22% to -$2.7 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered -$2.7 million, $11.2 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 12.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.45 Mn |
| Dec 31, 2025 | -2.71 Mn |
| Sep 30, 2025 | 11.19 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 3.19 Mn |
| Dec 31, 2024 | 26.52 Mn |
| Sep 30, 2024 | 727,119.00 |
| Jun 30, 2024 | 7.39 Mn |
| Mar 31, 2024 | 837,445.00 |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 4.06 Mn |
| Jun 30, 2023 | 4.79 Mn |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 2.84 Mn |
| Sep 30, 2022 | 2.34 Mn |
| Jun 30, 2022 | 3.21 Mn |
| Mar 31, 2022 | 2.29 Mn |
| Dec 31, 2021 | 3.24 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Jun 30, 2021 | 2.52 Mn |